Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit

In July, Amy Schulman looked to be one of the most powerful women in Big Pharma. As part of CEO Ian Read's plan to split Pfizer's internal operations into three distinct units, he tapped Schulman to lead the company's vaccines, oncology and consumer healthcare business. Now, Schulman is out.

Ex-Merck R&D chief Kim to teach at Stanford med school

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Power struggle at Novartis? Not at all, new chairman says

Novartis Chairman Joerg Reinhardt and CEO Joe Jimenez were once in competition for the chief executive post. Jimenez won out; Reinhardt left to run Bayer Healthcare. Now, Reinhardt's back--but rather than wrest power away from Jimenez, he plans to give Jimenez more. 

GoBalto gets new CEO as founder Jae Chung steps down

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Japan's Takeda looks to outsider as it reaches for international status

Japanese drugmaker Takeda Pharmaceuticals saw an era end last year when generic versions of its top seller, diabetes drug Actos, hit the market. Now it is trying to usher in a bold new era by giving a non-Japanese executive a shot at being CEO at a particularly difficult time.

Former Roche exec Barron to head R&D at Google's Calico

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

National Human Genome Research Institute appoints director to new division

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

AstraZeneca's cuts mean fresh talent for U.K. startups

In 2011, AstraZeneca jettisoned about 1,200 employees when it shuttered its R&D shop near Nottingham, U.K., but now the city is home to 22 life sciences startups launched by the drugmaker's former workers.

Bristol-Myers rejigs top management to refocus commercial ops, beef up CFO role

Last week, Bristol-Myers Squibb said it would jettison some research programs, lay off workers and generally reorganize R&D. Now, CEO Lamberto Andreotti is rejigging the commercial side of the business. In the shuffle, current commercial chief Beatrice Cazala will be shunted aside, with current U.S. President Giovanni Caforio taking her place.

Teva fills CFO position as Desheh steps up to CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...